A Living & Adaptive

Intelligence Engine

Making every trial more responsive, every insight more actionable, & every patient journey more personalized.
Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison

A Living & Adaptive

Intelligence Engine

Making every trial more responsive, every insight more actionable, & every patient journey more personalized.
Imagene AI Hits $45M in Total Funding After Completing $23M Series B Led by Larry Ellison

Our Cross-Modality Intelligence Engine continuously learns from imaging, molecular, and clinical data through proprietary foundation models, large language models, and biology-tuned analysis engines. It empowers biopharma & clinical teams with advanced capabilities for biomarker discovery, mechanism of action exploration, and indication expansion by deriving meaningful insights across modalities, enabling more predictive, insight-driven workflows that optimize trial design and improve therapeutic success.

A transformative SaaS platform delivering adaptive capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas.

At its core are state-of-the-art multimodal foundation models — a scalable and generalizable backbone that continuously learns from imaging, molecular, and clinical data to drive the next generation of drugs and diagnostics.

Our Medical Advisory Board

World-Leading Experts at the Forefront of Healthcare & Precision Oncology

David Agus, MD.

Founding CEO

Ellison Medical Institute

Natasha Leighl, MD.

Princess Margaret Cancer Centre, University of Toronto

Christian Rolfo, MD., PhD.
The Ohio State University Comprehensive Cancer Center

Ross Camidge, MD., PhD.
University of Colorado Cancer Center, Aurora, Colorado

Tony Mok, MD.
Dept. of Clinical Oncology
Chinese University, Hong Kong

To submit a case, follow these steps: